Dermata Therapeutics, Inc.
DRMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $7 | $22 |
| - Cash | $3 | $7 | $6 | $11 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$3 | -$7 | $1 | $11 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$12 | $0 | -$10 | -$8 |
| % Margin | – | – | – | – |
| Net Income | -$12 | -$8 | -$10 | -$8 |
| % Margin | – | – | – | – |
| EPS Diluted | -80.32 | -399.81 | -139.2 | -152.7 |
| % Growth | 79.9% | -187.2% | 8.8% | – |
| Operating Cash Flow | -$11 | -$6 | -$9 | -$6 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$11 | -$6 | -$9 | -$6 |